Clinical Trial Update: Pembrolizumab Plus Lenvatinib in REcurrent ccRCC Patients Failing permbroLizUmab aDjuvant trEatment [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating pembrolizumab plus lenvatinib in recurrent clear cell renal cell carcinoma patients who failed prior adjuvant therapy; the study is not…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clear Cell Renal Cell Carcinoma

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)
• LENVIMA (lenvatinib)

Snippet

Sponsor: Gruppo Oncologico Italiano di Ricerca Clinica | Conditions: ccRCC | Phase 2 | Status: NOT_YET_RECRUITING